MeSH D004832 - absence epilepsy
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D004829:Generalized epilepsy
0 Companies
0 Drugs
Success rate
D000073376:Epileptic syndromes
D004832:
Absence epilepsy
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Ethosuximide | Ethosuximide | 1993-07-30 | |||
| Divalproex sodium | Divalproex | 2008-07-29 | ||||
| Mylan | Divalproex sodium | Divalproex | 2008-07-29 | |||
| AbbVie | Valproic acid | Depakene | 1982-01-01 | |||
| Divalproex sodium | Depakote | 1983-03-10 | ||||
| Valproic acid | Depacon | 1996-12-30 | ||||
| Pfizer | Ethosuximide | Zarontin | 1982-01-01 | |||
| Aurobindo Pharma | Divalproex sodium | Divalproex | 2011-04-21 | |||
| Sun Pharmaceutical Industries | Valproic acid | Valproic Acid | 2013-02-22 | |||
| Divalproex sodium | Divalproex | 2008-07-29 | ||||
| Alembic Pharmaceuticals | Divalproex sodium | Divalproex | 2024-12-19 |
1
2
3
4
5
6
>
Clinical Trials
Historical Success Rate
Phase 1
0%0/0
Phase 2
0%0/1
Phase 3
73%8/11
Approved: 6Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use